Business
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive TreatmentIncreased
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive TreatmentIncreased Patient Demand, Manufacturing Capacity and Time to Treatment Highlighted as the Top Three Challenges Facing Future CAR T AdoptionInitiative Aims to Address Access Bottleneck by Accelerating Clinical Trial Enrollment for “Off-the-Shelf” Allogeneic Products SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today launched CAR T Together™, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers. A Media Snippet accompanying this announcement is available by clicking on the image or link below: CAR T Together was created in response to several real-world access challenges that have emerged since the commercial introduction of autologous CAR T five years ago – chief among them, the supply bottleneck created given the complex, individualized manufacturing process inherent in their delivery. This inaugural group aims to support innovation and bring awareness to clinical trials that may ultimately lead to the availability of an allogeneic CAR T product for patients. A new survey of U.S. based academic centers specializing in the administration of CAR T, found that 82% of respondents agreed that CAR T therapies have changed how they manage aggressive cancers, but extensive wait times and manufacturing limitations keep many eligible patients from receiving treatment.1 While the vast majority of late-stage cancer patients are eligible for CAR T treatment, only half of patients who are eligible for currently FDA approved autologous CAR T therapies receive treatment, according to the survey.1 Of those patients eligible for treatment, 12% were able to receive treatment within one month, with approximately 40% waiting three to six months or longer to receive treatment as their disease worsens.1 To improve access bottlenecks, CAR T Together brings together oncologists f...